These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 35670432)

  • 1. A phenolic based tumor-permeated nano-framework for immunogenic cell death induction combined with PD-L1 immune checkpoint blockade.
    Sun X; Zhang J; Xiu J; Zhao X; Yang C; Li D; Li K; Hu H; Qiao M; Chen D; Zhao X
    Biomater Sci; 2022 Jul; 10(14):3808-3822. PubMed ID: 35670432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phenolic immunogenic cell death nanoinducer for sensitizing tumor to PD-1 checkpoint blockade immunotherapy.
    Xie L; Wang G; Sang W; Li J; Zhang Z; Li W; Yan J; Zhao Q; Dai Y
    Biomaterials; 2021 Feb; 269():120638. PubMed ID: 33421711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peptide vaccine-conjugated mesoporous carriers synergize with immunogenic cell death and PD-L1 blockade for amplified immunotherapy of metastatic spinal.
    Wang Z; Chen L; Ma Y; Li X; Hu A; Wang H; Wang W; Li X; Tian B; Dong J
    J Nanobiotechnology; 2021 Aug; 19(1):243. PubMed ID: 34384429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
    Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H
    Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancement of anti-PD-1/PD-L1 immunotherapy for osteosarcoma using an intelligent autophagy-controlling metal organic framework.
    Ge YX; Zhang TW; Zhou L; Ding W; Liang HF; Hu ZC; Chen Q; Dong J; Xue FF; Yin XF; Jiang LB
    Biomaterials; 2022 Mar; 282():121407. PubMed ID: 35217343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted delivery of anti-miRNA21 sensitizes PD-L1
    Kim EH; Choi J; Jang H; Kim Y; Lee JW; Ryu Y; Choi J; Choi Y; Chi SG; Kwon IC; Yang Y; Kim SH
    Theranostics; 2024; 14(10):3777-3792. PubMed ID: 38994018
    [No Abstract]   [Full Text] [Related]  

  • 7. Construction of Hierarchically Biomimetic Iron Oxide Nanosystems for Macrophage Repolarization-Promoted Immune Checkpoint Blockade of Cancer Immunotherapy.
    Kang Y; Yan J; Han X; Wang X; Wang Y; Song P; Su X; Rauf A; Jin X; Pu F; Zhang H
    ACS Appl Mater Interfaces; 2024 Jul; 16(28):36131-36141. PubMed ID: 38979627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Local and Targeted Delivery of Immune Checkpoint Blockade Therapeutics.
    Han X; Li H; Zhou D; Chen Z; Gu Z
    Acc Chem Res; 2020 Nov; 53(11):2521-2533. PubMed ID: 33073988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-PD-L1 peptide-conjugated prodrug nanoparticles for targeted cancer immunotherapy combining PD-L1 blockade with immunogenic cell death.
    Moon Y; Shim MK; Choi J; Yang S; Kim J; Yun WS; Cho H; Park JY; Kim Y; Seong JK; Kim K
    Theranostics; 2022; 12(5):1999-2014. PubMed ID: 35265195
    [No Abstract]   [Full Text] [Related]  

  • 10. Genetically engineered cellular nanoparticles loaded with curcuminoids for cancer immunotherapy.
    Liao Y; Zhao C; Pan Y; Guo Y; Liu L; Wu J; Zhang Y; Rao L; Li Q
    Theranostics; 2024; 14(16):6409-6425. PubMed ID: 39431008
    [No Abstract]   [Full Text] [Related]  

  • 11. Anti-PD-L1 mediating tumor-targeted codelivery of liposomal irinotecan/JQ1 for chemo-immunotherapy.
    He ZD; Zhang M; Wang YH; He Y; Wang HR; Chen BF; Tu B; Zhu SQ; Huang YZ
    Acta Pharmacol Sin; 2021 Sep; 42(9):1516-1523. PubMed ID: 33311600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Multifunctional Biomimetic Nanoplatform for Relieving Hypoxia to Enhance Chemotherapy and Inhibit the PD-1/PD-L1 Axis.
    Zou MZ; Liu WL; Li CX; Zheng DW; Zeng JY; Gao F; Ye JJ; Zhang XZ
    Small; 2018 Jul; 14(28):e1801120. PubMed ID: 29882235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune Checkpoint Blockade Mediated by a Small-Molecule Nanoinhibitor Targeting the PD-1/PD-L1 Pathway Synergizes with Photodynamic Therapy to Elicit Antitumor Immunity and Antimetastatic Effects on Breast Cancer.
    Zhang R; Zhu Z; Lv H; Li F; Sun S; Li J; Lee CS
    Small; 2019 Dec; 15(49):e1903881. PubMed ID: 31702880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tackling Esophageal Squamous Cell Carcinoma with ITFn-Pt(IV): A Novel Fusion of PD-L1 Blockade, Chemotherapy, and T-cell Activation.
    Xin Q; Wang D; Wang S; Zhang L; Liang Q; Yan X; Fan K; Jiang B
    Adv Healthc Mater; 2024 Apr; 13(11):e2303623. PubMed ID: 38142309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycyrrhetinic acid nanoparticles combined with ferrotherapy for improved cancer immunotherapy.
    Li Q; Su R; Bao X; Cao K; Du Y; Wang N; Wang J; Xing F; Yan F; Huang K; Feng S
    Acta Biomater; 2022 May; 144():109-120. PubMed ID: 35314366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Janus Silica Nanoparticle-Based Tumor Microenvironment Modulator for Restoring Tumor Sensitivity to Programmed Cell Death Ligand 1 Immune Checkpoint Blockade Therapy.
    Lin X; Li F; Guan J; Wang X; Yao C; Zeng Y; Liu X
    ACS Nano; 2023 Aug; 17(15):14494-14507. PubMed ID: 37485850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Binary regulation of the tumor microenvironment by a pH-responsive reversible shielding nanoplatform for improved tumor chemo-immunotherapy.
    Sun X; Zhang J; Zhao X; Yang C; Shi M; Zhang B; Hu H; Qiao M; Chen D; Zhao X
    Acta Biomater; 2022 Jan; 138():505-517. PubMed ID: 34798317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reprogramming the Tumor Microenvironment through Second-Near-Infrared-Window Photothermal Genome Editing of PD-L1 Mediated by Supramolecular Gold Nanorods for Enhanced Cancer Immunotherapy.
    Tang H; Xu X; Chen Y; Xin H; Wan T; Li B; Pan H; Li D; Ping Y
    Adv Mater; 2021 Mar; 33(12):e2006003. PubMed ID: 33538047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phototheranostic Metal-Phenolic Networks with Antiexosomal PD-L1 Enhanced Ferroptosis for Synergistic Immunotherapy.
    Xie L; Li J; Wang G; Sang W; Xu M; Li W; Yan J; Li B; Zhang Z; Zhao Q; Yuan Z; Fan Q; Dai Y
    J Am Chem Soc; 2022 Jan; 144(2):787-797. PubMed ID: 34985903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.